外泌体在原发性胆汁性胆管炎中作用的研究进展

马海涛; 唐映梅

doi:10.3969/j.issn.1001-5256.2022.08.035

外泌体在原发性胆汁性胆管炎中作用的研究进展

DOI: 10.3969/j.issn.1001-5256.2022.08.035

马海涛,
唐映梅^, ,

昆明医科大学第二附属医院消化内科，昆明 650101

基金项目:

国家自然科学基金项目 (81760107);

云南省自然科学基金项目 (2018FE001〔-051〕);

昆明医科大学研究生创新基金项目 (2021S050)

利益冲突声明：所有作者均不存在利益冲突。

作者贡献声明：马海涛负责起草文章，对行文的思路和设计有关键贡献；唐映梅参与了修改文章关键内容。

详细信息

通信作者:
唐映梅，tangyingmei_med@kmmu.edu.cn

计量
- 文章访问数: 564
- HTML全文浏览量: 106
- PDF下载量: 75
- 被引次数: 0
出版历程
- 收稿日期: 2021-12-06
- 录用日期: 2022-01-15
- 出版日期: 2022-08-20

Research advances in exosomes in primary biliary cholangitis

Haitao MA,
Yingmei TANG^{,
,}

Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China

Research funding:

National Natural Science Foundation of China (81760107);

Natural Science Foundation of Yunnan Province (2018FE001〔-051〕);

Graduate student Innovation Fund of Kunming Medical University (2021S050)

More Information

Corresponding author: TANG Yingmei, tangyingmei_med@kmmu.edu.cn(ORCID:0000-0002-0731-4198)

摘要

摘要: 原发性胆汁性胆管炎(PBC)是一种以胆汁淤积为特征的自身免疫性疾病。近年来国内外多项研究表明，外泌体在PBC疾病的发生发展中发挥重要作用，是目前医学研究领域的一大热点。本文主要从外泌体在PBC发病中的作用及其在PBC诊断和治疗中的研究进展等方面展开综述。外泌体在PBC疾病中的应用前景十分广阔，深入研究外泌体也将为PBC的诊疗带来新的机遇。
- 原发性胆汁性胆管炎 /
- 外泌体 /
- 诊断 /
- 治疗学
Abstract: Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by cholestasis. In recent years, a number of studies in China and globally have shown that exosomes play an important role in the development and progression of PBC, which is currently a hotspot in the field of medical research. This article reviews the role of exosomes in the pathogenesis of PBC and related research advances in the diagnosis and treatment of PBC. It is believed that exosomes have wide application prospect in PBC, and in-depth research on exosomes may bring new opportunities for the diagnosis and treatment of PBC.
- Primary Biliary Cholangitis /
- Exosomes /
- Diagnosis /
- Therapeutics

HTML全文

图 1 外泌体在PBC疾病中的作用机制示意图

注：a，循环外泌体调节不同APC共刺激分子差异表达；b，胆管细胞来源的外泌体H19向Kupffer细胞和HSC内转移，产生多种生物学效应。

Figure 1. The schematic diagram of the role of exosomes in PBC disease

下载: 全尺寸图片幻灯片

参考文献(43)

[1]	LLEO A, WANG G, GERSHWIN M, et al. Primary biliary cholangitis[J]. Lancet (London, England), 2020, 396(10266): 1915-1926. DOI: 10.1016/S0140-6736(20)31607-X.
[2]	GULAMHUSEIN AF, HIRSCHFIELD GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(2): 93-110. DOI: 10.1038/s41575-019-0226-7.
[3]	YOKODA RT, CAREY EJ. Primary biliary cholangitis and primary sclerosing cholangitis[J]. Am J Gastroenterol, 2019, 114(10): 1593-1605. DOI: 10.14309/ajg.0000000000000268.
[4]	BANALES JM, HUEBERT RC, KARLSEN T, et al. Cholangiocyte pathobiology[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(5): 269-281. DOI: 10.1038/s41575-019-0125-y.
[5]	PEGTEL DM, GOULD SJ. Exosomes[J]. Annu Rev Biochem, 2019, 88: 487-514. DOI: 10.1146/annurev-biochem-013118-111902.
[6]	JIAO Y, XU P, SHI H, et al. Advances on liver cell-derived exosomes in liver diseases[J]. J Cell Mol Med, 2021, 25(1): 15-26. DOI: 10.1111/jcmm.16123.
[7]	van NIEL G, D'ANGELO G, RAPOSO G. Shedding light on the cell biology of extracellular vesicles[J]. Nat Rev Mol Cell Biol, 2018, 19(4): 213-228. DOI: 10.1038/nrm.2017.125.
[8]	SUNG S, KIM J, JUNG Y. Liver-derived exosomes and their implications in liver pathobiology[J]. Int J Mol Sci, 2018, 19(12): 3715. DOI: 10.3390/ijms19123715.
[9]	DUAN W, ZHANG W, JIA J, et al. Exosomal microRNA in autoimmunity[J]. Cell Mol Immunol, 2019, 16(12): 932-934. DOI: 10.1038/s41423-019-0319-9.
[10]	KALLURI R, LEBLEU VS. The biology, function, and biomedical applications of exosomes[J]. Science, 2020, 367(6478): eaau6977. DOI: 10.1126/science.aau6977.
[11]	ANEL A, GALLEGO-LLEYDA A, de MIGUEL D, et al. Role of Exosomes in the regulation of T-cell mediated immune responses and in autoimmune disease[J]. Cells, 2019, 8(2): 154. DOI: 10.3390/cells8020154.
[12]	MIAO C, WANG X, ZHOU W, et al. The emerging roles of exosomes in autoimmune diseases, with special emphasis on microRNAs in exosomes[J]. Pharmacol Res, 2021, 169: 105680. DOI: 10.1016/j.phrs.2021.105680.
[13]	MA WT, CHEN DK. Immunological abnormalities in patients with primary biliary cholangitis[J]. Clin Sci (Lond), 2019, 133(6): 741-760. DOI: 10.1042/CS20181123.
[14]	TOMIYAMA T, YANG GX, ZHAO M, et al. The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis[J]. Cell Mol Immunol, 2017, 14(3): 276-284. DOI: 10.1038/cmi.2015.86.
[15]	CHENG J, WU R, LONG L, et al. miRNA-451a Targets IFN regulatory factor 8 for the progression of systemic lupus erythematosus[J]. Inflammation, 2017, 40(2): 676-687. DOI: 10.1007/s10753-017-0514-8.
[16]	FOTOH DS, NORELDIN RI, RIZK M S, et al. miRNA-451a and miRNA-125a expression levels in ankylosing spondylitis: impact on disease diagnosis, prognosis, and outcomes[J]. J Immunol Res, 2020, 2020: 2180913. DOI: 10.1155/2020/2180913.
[17]	SHEN J, HUANG CK, YU H, et al. The role of exosomes in hepatitis, liver cirrhosis and hepatocellular carcinoma[J]. J Cell Mol Med, 2017, 21(5): 986-992. DOI: 10.1111/jcmm.12950.
[18]	AL SURAIH MS, TRUSSONI CE, SPLINTER PL, et al. Senescent cholangiocytes release extracellular vesicles that alter target cell phenotype via the epidermal growth factor receptor[J]. Liver Int, 2020, 40(10): 2455-2468. DOI: 10.1111/liv.14569.
[19]	POPE C, MISHRA S, RUSSELL J, et al. Targeting H19, an imprinted long non-coding RNA, in hepatic functions and liver diseases[J]. Diseases, 2017, 5(1) : 11. DOI: 10.3390/diseases5010011.
[20]	LI X, LIU R, HUANG Z, et al. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans[J]. Hepatology, 2018, 68(2): 599-615. DOI: 10.1002/hep.29838.
[21]	LIU R, LI X, ZHU W, et al. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis[J]. Hepatology, 2019, 70(4): 1317-1335. DOI: 10.1002/hep.30662.
[22]	REUVENI D, BREZIS MR, BRAZOWSKI E, et al. Interleukin 23 produced by hepatic monocyte-derived macrophages is essential for the development of murine primary biliary cholangitis[J]. Front Immunol, 2021, 12: 718841. DOI: 10.3389/fimmu.2021.718841.
[23]	LI X, LIU R, WANG Y, et al. Cholangiocyte-derived exosomal lncRNA H19 promotes macrophage activation and hepatic inflammation under cholestatic conditions[J]. Cells, 2020, 9(1): 190. DOI: 10.3390/cells9010190.
[24]	CHEN S, JIANG T, LIN H, et al. Fast and ultrasensitive visual detection of exosomes in body fluids for point-of-care disease diagnosis[J]. Anal Chem, 2021, 93(29): 10372-10377. DOI: 10.1021/acs.analchem.1c02136.
[25]	SHAO H, IM H, CASTRO CM, et al. New technologies for analysis of extracellular vesicles[J]. Chem Rev, 2018, 118(4): 1917-1950. DOI: 10.1021/acs.chemrev.7b00534.
[26]	JIAO Y, LU W, XU P, et al. Hepatocyte-derived exosome may be as a biomarker of liver regeneration and prognostic valuation in patients with acute-on-chronic liver failure[J]. Hepatol Int, 2021, 15(4): 957-969. DOI: 10.1007/s12072-021-10217-3.
[27]	COLAPIETRO F, LIEO A, GENERALI E. Antimitochondrial antibodies: from bench to bedside[J]. Clin Rev Allergy Immunol, 2021, 29: 1-12. DOI: 10.1007/s12016-021-08904-y.
[28]	de RIE D, ABUGESSAISA I, ALAM T, et al. An integrated expression atlas of miRNAs and their promoters in human and mouse[J]. Nat Biotechnol, 2017, 35(9): 872-878. DOI: 10.1038/nbt.3947.
[29]	MORI MA, LUDWIG RG, GARCIA-MARTIN R, et al. Extracellular miRNAs: From biomarkers to mediators of physiology and disease[J]. Cell Metab, 2019, 30(4): 656-673. DOI: 10.1016/j.cmet.2019.07.011.
[30]	OLAIZOLA P, LEE-LAW PY, ARBELAIZ A, et al. MicroRNAs and extracellular vesicles in cholangiopathies[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B): 1293-1307. DOI: 10.1016/j.bbadis.2017.06.026.
[31]	WASIK U, KEMPINSKA-PODHORODECKA A, BOGDANOS DP, et al. Enhanced expression of miR-21 and miR-150 is a feature of anti-mitochondrial antibody-negative primary biliary cholangitis[J]. Mol Med, 2020, 26(1): 8. DOI: 10.1186/s10020-019-0130-1.
[32]	STATELLO L, GUO CJ, CHEN LL, et al. Gene regulation by long non-coding RNAs and its biological functions[J]. Nat Rev Mol Cell Biol, 2021, 22(2): 96-118. DOI: 10.1038/s41580-020-00315-9.
[33]	SHAH R, PATEL T, FREEDMAN JE. Circulating extracellular vesicles in human disease[J]. N Engl J Med, 2018, 379(10): 958-966. DOI: 10.1056/NEJMra1704286.
[34]	GUO N, ZHOU Q, HUANG X, et al. Identification of differentially expressed circulating exosomal lncRNAs in IgA nephropathy patients[J]. BMC Immunol, 2020, 21(1): 16. DOI: 10.1186/s12865-020-00344-1.
[35]	SUN Z, YANG S, ZHOU Q, et al. Emerging role of exosome-derived long non-coding RNAs in tumor microenvironment[J]. Mol Cancer, 2018, 17(1): 82. DOI: 10.1186/s12943-018-0831-z.
[36]	WANG L, ZHANG J. Exosomal lncRNA AK139128 Derived from Hypoxic cardiomyocytes promotes apoptosis and inhibits cell proliferation in cardiac fibroblasts[J]. Int J Nanomedicine, 2020, 15: 3363-3376. DOI: 10.2147/IJN.S240660.
[37]	KHURANA R, RANCHES G, SCHAFFERER S, et al. Identification of urinary exosomal noncoding RNAs as novel biomarkers in chronic kidney disease[J]. RNA, 2017, 23(2): 142-152. DOI: 10.1261/rna.058834.116.
[38]	LI Y, TANG R, MA X. Epigenetics of primary biliary cholangitis[J]. Adv Exp Med Biol, 2020, 1253: 259-283. DOI: 10.1007/978-981-15-3449-2_10.
[39]	RODRIGUES PM, PERUGORRIA MJ, SANTOS-LASO A, et al. Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?[J]. J Hepatol, 2018, 69(6): 1371-1383. DOI: 10.1016/j.jhep.2018.08.020.
[40]	GANG D, YU CJ, ZHU S, et al. Application of mesenchymal stem cell-derived exosomes in kidney diseases[J]. Cell Immunol, 2021, 364: 104358. DOI: 10.1016/j.cellimm.2021.104358.
[41]	LOU G, CHEN Z, ZHENG M, et al. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases[J]. Exp Mol Med, 2017, 49(6): e346. DOI: 10.1038/emm.2017.63.
[42]	RONG X, LIU J, YAO X, et al. Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/β-catenin pathway[J]. Stem Cell Res Ther, 2019, 10(1): 98. DOI: 10.1186/s13287-019-1204-2.
[43]	CHEN W, ZHU J, LIN F, et al. Human placenta mesenchymal stem cell-derived exosomes delay H₂O₂-induced aging in mouse cholangioids[J]. Stem Cell Res Ther, 2021, 12(1): 201. DOI: 10.1186/s13287-021-02271-3.